RPE65 and Leber congenital amaurosis: Focus on this pathology mechanism has grown rapidly because of the United States Food and Drug Administration’s 2017 approval of Luxturna (voretigene neparvovec-rzyl), a form of one-time gene therapy, to treat RPE65 mutations in LCA patients.